BROADWOOD PARTNERS LP 13D and 13G filings for OncoCyte Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-04-07 10:38 am Purchase |
2023-04-03 | 13D | OncoCyte Corporation OCX |
BROADWOOD PARTNERS LP | 2,856,559 33.300% |
1,345,914 (+89.10%) |
Filing |
| 2022-07-28 5:06 pm Purchase |
2022-07-21 | 13D | OncoCyte Corporation OCX |
BROADWOOD PARTNERS LP | 1,510,645 24.100% |
321,897 (+27.08%) |
Filing |
| 2022-04-15 5:21 pm Purchase |
2022-04-13 | 13D | OncoCyte Corporation OCX |
BROADWOOD PARTNERS LP | 1,188,748 19.990% |
296,969 (+33.30%) |
Filing |
| 2021-09-24 4:40 pm Unchanged |
2021-09-23 | 13D | OncoCyte Corporation OCX |
BROADWOOD PARTNERS LP | 891,780 19.300% |
0 (Unchanged) |
Filing |
| 2021-02-09 5:10 pm Purchase |
2021-02-05 | 13D | OncoCyte Corporation OCX |
BROADWOOD PARTNERS LP | 891,780 20.100% |
30,000 (+3.48%) |
Filing |
| 2021-01-22 4:18 pm Purchase |
2021-01-20 | 13D | OncoCyte Corporation OCX |
BROADWOOD PARTNERS LP | 861,780 21.600% |
253,911 (+41.77%) |
Filing |